Industry’s anxieties about the pharmaceutical quality metrics guidance FDA drafted in July boiled over in an Aug. 24 meeting at FDA’s Silver Spring, Md., headquarters.
Groups for brand and generic drug makers, so often at odds in Washington, agreed on one point: FDA has no authority to make